Ovulation triggering in clomiphene citrate-stimulated cycles: human chorionic gonadotropin versus a gonadotropin releasing hormone agonist

What Was Tested

This randomized controlled trial looks at hCG (human chorionic gonadotropin) and Nafarelin.

To compare the use of human chorionic gonadotropin (hCG) to a gonadotropin releasing hormone (GnRH) agonist, nafarelin, in initiating ovulation and supporting the luteal phase after priming with clomiphene.

Who Took Part

According to the abstract, 26 women were involved.

The age groups tagged for this paper are adults, women only.

On LD13, endometrium was evaluated with ultrasonography and biopsy in 19 nonpregnant women.

How the Study Was Run

In design terms this was a randomized study.

Random assignment meant chance, not the researchers, decided who got hCG (human chorionic gonadotropin) and who got the comparison, which limits bias.

Serum levels of follicle stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E2), progesterone (P), and hCG were measured.

What Was Measured

The subject headings attached to it are Biopsy, Chorionic Gonadotropin, Clomiphene, Endometrium, Estradiol, Fertility Agents, Female and Follicle Stimulating Hormone.

What This Means in Plain Language

The paper is a randomized study of hCG (human chorionic gonadotropin) and Nafarelin in 26 women.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 1995 (Journal of assisted reproduction and genetics), a journal based in Netherlands.

More context: the hCG (human chorionic gonadotropin) compound page and the Nafarelin compound page, all human trials.